Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners

The episode opens with a discussion of new audio and multilingual content features now available to BioCentury subscribers. Lauren Martz presents an analysis of multinational pharma partnerships with Chinese biotech companies, revealing nine more deals year-to-date compared to the previous year. Notably, recent major deals from Merck, Novo, and Novartis involve early-stage, high-value assets ($300M+ upfronts, $2B+ total values) across diverse modalities and disease areas—a shift from historical patterns focused on antibody therapies and cancer. These deals demonstrate innovation coming from China, including an RNA-encoded T-cell engager from Avagen and a KRAS G12D molecular glue from Cybrunch. Steve Usden discusses Washington's concerns about co-development arrangements between multinational and Chinese companies, noting that Treasury officials focus on co-development deals rather than simple licensing as the primary threat to U.S. innovation. Frank Ledoux's commentary argues that Chinese assets going global doesn't equate to Chinese companies becoming true multinational entities.

Steve Usden then covers Beam Therapeutics' lawsuit against Yoltec and its CEO Jensen Wu, alleging trade secret theft by former scientist Emma Wang, who allegedly co-founded Yoltec while employed at Beam. The suit involves 19 categories of alleged misappropriated technology and claims of negative know-how—knowledge of what didn't work enabling faster development. Yoltec's product is an LNP-delivered base editor targeting the same Alpha-1 antitrypsin deficiency mutation as Beam's, but Usden notes that shared targets and technologies don't necessarily indicate theft. Defendants deny allegations, with Wang claiming contemporaneous R&D records exist and pointing to Beam's prior public disclosures of research steps. Usden emphasizes the case's complexity, noting that previous litigation between Beam and Prime Medicine over similar allegations resulted in Prime's victory in arbitration.

Regarding drug pricing, Usden explains that the GLOBE model (mandatory most-favored-nation pricing for Medicare Part B) has dramatically shrunk from projected $11.9 billion savings over seven years to approximately $440 million, affecting only two to four undisclosed companies. Exemptions include companies accepting MFN pricing in Medicaid, gene and cell therapies, orphan-only drugs, plasma-derived products, and drugs facing biosimilar competition. Usden argues the shrinkage clarifies that the precedent matters more than immediate savings—the precedent being CMS's use of demonstration authority to impose international reference pricing without Congressional action. He notes that pharma CEOs' prior acceptance of foreign price benchmarking now constrains their positions, and Democrats are likely to cite this precedent in future drug pricing initiatives. The related GARD model for Medicare Part D prescription drugs is set to begin January 1, 2025.

The episode concludes with discussion of the 2024 Nobel Prize in Physiology or Medicine awarded for optogenetics research. Selena Koch explains that optogenetics uses light-sensitive opsin proteins to control specific neural circuits, allowing researchers to activate or inhibit cell types genetically and observe circuit and behavioral effects. This technology has primarily served as a research tool for understanding disease biology in dementia and psychiatric conditions, though therapeutic applications exist in ophthalmology where opsins can restore light sensitivity to remaining cells after photoreceptor degeneration. Selena notes that 2015 interview with laureate Karl Deisseroth revealed his emphasis on basic research tools' unexpected applications and his skepticism of top-down moonshot approaches to solving neurodegenerative diseases.